Rev. Fac. Med. Hum. January 2020;20(1):12-13.

## PERSPECTIVES FOR HEALTH TECHNOLOGY ASSESSMENT

PERSPECTIVAS PARA LA EVALUACIÓN DE TECNOLOGÍAS DE SALUD

Marcus Tolentino-Silva<sup>1,a</sup>

An unplanned health care system is like a paper boat carried by a slowly sinking current. In times of disinformation and excessive distraction, investing in better facts on health technology assessment (HTA) will enable more active actions rather than reactive to the market dynamics. This paper aims to raise some reflections on HTA in terms of political context, health technologies and epidemiological priorities.

The perspective of HTA is context dependent, intrinsic to its political and institutional articulation. At the moment, the paradox is to maintain a specialized structure in the face of economic austerity policies that reduce health resources, and a scenario of greater interest in raising public funds by the private sector. Particularly in Brazil, HTA will also have to deal with the gradual shift from a universal health system to a minimum portfolio of services offered by the private sector<sup>1</sup>. The public sector will be requested for very expensive technologies, usually by judicial measures. The precariousness of work relationships will influence HTA workers because they will not have a link and identity with the health system. Thus, there will be more productive and less reflective HTA processes. The context of greater dependence on the private market will allow new problems with medical technologies to emerge, such as the opioid crisis in the United States.

Health technologies will continue to put pressure on health systems. The last decade has been marked by the use of high cost biological drugs. Others advanced therapy medicinal products are expected to have this momentum in the coming years<sup>2</sup>. In addition, there will be greater integration between diagnostic and treatment technologies (e.g., glucose monitoring devices and insulin pumps) and more information about these products performance. The HTA specialist will have to keep up with this knowledge and reflect on how the undesirable consequences of these products will be detected. It is noteworthy that the high technological dependence will make underdeveloped countries prioritize market needs over those public health.

Underdevelopment induces reliance on essential technologies, such as the need to import basic active ingredients (e.g. penicillin), and the reversal of science and technology priorities when thinking about health needs. In consequence, ineffective procedures for poverty-related diseases will persist for many years<sup>3</sup>. The possibility of weakening governments and shifting responsibilities to the private sector will increase access inequality and new inputs will address the epidemiological priorities of developed countries. Mitigating health technology approval mechanisms will induce HTA to strengthen monitoring and new ways of reimbursement, such as risk-sharing.

Epidemiological challenges often push themselves on society. Going back to the Brazilian scenario, the past decade was marked the epidemiology of infectious diseases with the emergence of microcephaly associated with the Zika virus4. Despite it was a disease with little knowledgement, the country responded satisfactorily due to past years investments in research and development. However, the pandemic increased issues about social justice issues, like reproductive rights of women. Considering the possibility of further outbreaks and diseases, the answer will be uncertain because the sustainability of science and technology is out of priority. Accordingly, the HTA specialist will have to cope with the poorest information to induce health decisions. In the short term we will look at the health consequences of oil spills on beaches in northeastern Brazil, the increased access to pesticides and the use of electronic cigarettes. This group of problems will be merged by still persistent issues such as chronic and infectious diseases, in which they are related to more effective public policies to control risk factors in the population, such

Cite as: Marcus Tolentino-Silva. Perspectives for health technology assessment. Rev Rev. Fac. Med. Hum. January 2020; 20(1):12-13. DOI 10.25176/RFMH.v20i1.2562

Journal home page: http://revistas.urp.edu.pe/index.php/RFMH

Article published by the Journal of the Faculty of Human Medicine of the Ricardo Palma University. It is an open access article, distributed under the terms of the Creative Commons License: Creative Commons Attribution 4.0 International, CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/), which allows non-commercial use, distribution and reproduction in any medium, provided that the original work is duly cited. For commercial use, please contact magazine.medicina@urp.pe

<sup>&</sup>lt;sup>1</sup> University of Sorocaba, Brazil.

a BPharm, MSc, PhD.

as known harmful products (eg sugar, cigarettes, and alcohol) and sanitation.

The weakening scenario of the governments will be combine with the growth of conflicts of interest. Such conflicts will make HTA process more arduous, especially about outcomes measurements and the confidentiality of clinical trial data. For studies to have faster conclusions, surrogate and combined outcomes will become more frequent<sup>5</sup>. Bias regarding selectivity in reporting outcomes will be common, considering the fragility of approval process and the revolving door movement (people with private interest working in the public sector, and vice versa). There will also be an increase in qualitative studies on technology users' perceptions, which will be influenced by the Hawthorne effect (performance improvement by observation) and placebo effect (performance improvement as suggested), compared to a medical absence scenario.

The past decade has also been marked by new methodological approaches to assessing the performance

of medical technologies, including indirect comparisons, comparative effectiveness research, and new analytical models in cost-effectiveness studies. The HTA specialist will have to learn the issues of these approaches and how they will influence decision making<sup>6</sup>. This is an important challenge in a scenario of low investment in education. Training professionals with these skills depends on scholarships and access to good quality postgraduate courses. It is worth mentioning the expectation of a larger number of unconventional databases in terms of structure and size (big data) and the use of artificial intelligence in health decisions and in the right of access to services.

In the medium to long term, it is clear that the health systems we know will sink and change the processes of HTA. These changes are slow and sometimes difficult to perceive, as the search for medical care is irregular, especially in underdeveloped contexts. Further reflection on these aspects will enable more active behavior by managers and politics committed to a more equalitarian and just society.

Correspondence: Marcus Tolentino Silva.

Address: Universidade de Sorocaba, Pós-Graduação, Sala 13, Rodovia Raposo Tavares, km 92,5, Sorocaba, São Paulo-Brasil.

Telephone: +55 19991496311 E-mail: marcusts@gmail.com

## **BIBLIOGRAPHIC REFERENCES**

- 1. Paes-Sousa R, Schramm JMA, Mendes LVP. Fiscal austerity and the health sector: the cost of adjustments. Cien Saude Colet. 2019 Dec;24(12):4375-4384. Avaliable at: https://doi.org/10.1590/1413-812320182412.23232019.
- 2. Jönsson B, Hampson G, Michaels J, Towse A, von der Schulenburg JG, Wong O. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare. Eur J Health Econ. 2019 Apr;20(3):427-438. Avaliable at: https://doi.org/10.1007/s10198-018-1007-x.
- 3. Malecela MN. Reflections on the decade of the neglected tropical diseases. Int Health. 2019 Sep 2;11(5):338-340. Available at: https://doi.org/10.1093/inthealth/ihz048.
- 4. Musso D, Ko Al, Baud D. Zika Virus Infection After the Pandemic. N

- Engl J Med. 2019 Oct 10;381(15):1444-1457. Avaliable at: https://doi.org/10.1056/NEJMra1808246.
- 5. Ribeiro TB, Ribeiro A, Rodrigues LO, Harada G, Nobre MRC. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer. Int J Technol Assess Health Care. 2019 Nov 28:1-9. Avaliable at: https://doi.org/10.1017/S0266462319000813.
- 6. Akhras KS, Alsheikh-Ali AA, Kabbani S. Use of real-world evidence for healthcare decision-making in the Middle East: practical considerations and future directions. Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):245-250. Avaliable at: https://doi.org/10.1080/14737167.201 9.1568243.

Acknowledgments: Taís Freire Galvão (notes and proofreading).